Bumper Offer - Urjas oil Just @ Rs. 1
Zyrova 40 Tablet is a commercial drug that is prescribed in the form of Tablet. It is primarily used for the treatment of High Cholesterol. The alternative uses of Zyrova 40 Tablet have also been explained below.
Medical history of the patient along with age and gender determines the dosage of Zyrova 40 Tablet. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
Some other side effects of Zyrova 40 Tablet have been listed ahead. Normally, these side effects of Zyrova 40 Tablet are not long lasting and go away when the treatment is finished. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Zyrova 40 Tablet's effect during pregnancy is Severe and Mild while nursing. It is important to know if Zyrova 40 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Zyrova 40 Tablet related warnings section.
Zyrova 40 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Kidney Disease, Hypothyroidism, Drug Allergy are examples of such conditions. Other contraindications of Zyrova 40 Tablet have been discussed in the sections ahead.
Additionally, Zyrova 40 Tablet may also adversely react with other medicines. See below for a complete list.
In addition to the above precautions for Zyrova 40 Tablet, it is important to know that it is safe while driving, and is habit-forming.
Zyrova 40 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Is the use of Zyrova 40 Tablet safe for pregnant women?
Pregnant women may get severe side effects after taking Zyrova. If you are pregnant, do not take Zyrova without a doctor's advice.
Is the use of Zyrova 40 Tablet safe during breastfeeding?
Zyrova has been seen to have minimal side effects on breastfeeding women.
What is the effect of Zyrova 40 Tablet on the Kidneys?
Zyrova can have moderate side effects on the kidney. If you notice any harmful effects, stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Zyrova 40 Tablet on the Liver?
You may experience side effects on your liver after taking Zyrova. If this happens, then discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Zyrova 40 Tablet on the Heart?
Zyrova is rarely harmful for the heart.
Zyrova 40 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Zyrova 40 Tablet unless your doctor advises you to do so -
Is this Zyrova 40 Tablet habit forming or addictive?
No, there is no any evidence that Zyrova 40 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Zyrova 40 Tablet does not cause dizziness or sleep, so you can drive a vehicle or operate machinery also.
Is it safe?
Yes, but consume Zyrova 40 Tablet only on doctor's advice.
Is it able to treat mental disorders?
Zyrova 40 Tablet is unable to treat or cure mental disorders.
Interaction between Food and Zyrova 40 Tablet
Some foods when eaten with Zyrova 40 Tablet can alter the onset of actions. Discuss this with your doctor.
Interaction between Alcohol and Zyrova 40 Tablet
Consuming Zyrova 40 Tablet with alcohol can have many serious effects on your body.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650